Skip to main content

Healthy Adults

22
Pipeline Programs
20
Companies
41
Clinical Trials
7 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
21
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
150%
Vaccine
150%
+ 39 programs with unclassified modality

Competitive Landscape

20 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
9 programs
8
1
Vaccine Candidate #1Phase 2Vaccine1 trial
PF-07104091Phase 12 trials
PF-07220060Phase 11 trial
PF-07220060Phase 12 trials
PF-07248144Phase 13 trials
+4 more programs
Active Trials
NCT07127770Completed9Est. Nov 2025
NCT04553133Active Not Recruiting157Est. Dec 2026
NCT07160738Completed25Est. Dec 2025
+10 more trials
Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
2
EC5026 oral capsulePhase 11 trial
EC5026 oral tabletPhase 11 trial
DietaryN/A1 trial
Active Trials
NCT01402973Completed24Est. Nov 2011
NCT04228302Completed40Est. Jul 2020
NCT04908995Completed18Est. Nov 2021
Luye Pharma
Luye PharmaChina - Shanghai
3 programs
3
LY01011Phase 11 trial
LY06006Phase 11 trial
LY06006Phase 11 trial
Active Trials
NCT04198636Unknown168Est. Jun 2021
NCT04973722Unknown168Est. Dec 2021
NCT03427853Unknown32Est. Dec 2019
EicOsis
EicOsisCA - Davis
2 programs
2
EC5026 oral capsulePhase 1
EC5026 oral tabletPhase 1
Kaken Pharmaceutical
2 programs
2
KP-001Phase 11 trial
KP-001Phase 11 trial
Active Trials
NCT06619054Completed24Est. Jul 2025
NCT06227832Completed38Est. Jul 2024
Metro Biotech
2 programs
2
MIB-725Phase 11 trial
Nicotinamide MononucleotidePhase 1Peptide1 trial
Active Trials
NCT06815991Recruiting32Est. Mar 2027
NCT06882096Recruiting32Est. Jun 2027
Dong-A ST
Dong-A STKorea - Seoul
1 program
1
Diluted Intravenous DA-5217Phase 11 trial
Active Trials
NCT07027982Completed32Est. Aug 2025
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
SC MethylnaltrexonePhase 11 trial
Active Trials
NCT01367535Completed54Est. Aug 2006
Tonix Pharmaceuticals
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
4 programs
SL TNX-102 2.4 mg at pH 3.5PHASE_11 trial
SL TNX-102 at 2.4 mgPHASE_11 trial
TNX-102 SL Tablets at 2.8 mgPHASE_11 trial
Treatment APHASE_11 trial
Active Trials
NCT01634412Completed24Est. Jan 2014
NCT01689259Completed24Est. Mar 2014
NCT01889173Completed24Est. Mar 2014
+1 more trials
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
3 programs
CORT113176PHASE_11 trial
CORT113176 Lipid Capsule FormulationPHASE_11 trial
DazucorilantPHASE_11 trial
Active Trials
NCT04994743Completed16Est. Sep 2021
NCT04249323Completed110Est. Oct 2020
NCT06495944Completed21Est. Aug 2024
Innovation Pharmaceuticals
2 programs
1-Increased water intake regimenN/A1 trial
WaterN/A1 trial
Active Trials
NCT01583387Completed65Est. Oct 2011
NCT02044679Completed82Est. Mar 2014
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
BlueberriesN/A1 trial
Active Trials
NCT05967897Completed19Est. Jun 2024
Gravitas Medical
Gravitas MedicalCA - San Francisco
1 program
Feeding tubeN/A
TheraNova
TheraNovaCA - San Francisco
1 program
Feeding tubeN/A1 trial
Active Trials
NCT06660758Recruiting40Est. Dec 2025
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
Juvederm® VOLITEN/A1 trial
Active Trials
NCT04206293Completed11Est. Jul 2020
Origin
OriginRUSTON, LA
1 program
SuperHMON/A1 trial
Active Trials
NCT06570330Completed32Est. Jul 2025
Lumos Pharma
Lumos PharmaTX - Austin
1 program
Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based ProgramN/A1 trial
Active Trials
NCT06376175Completed37Est. Jan 2025
Roche
RocheSTAVANGER NORWAY, Norway
1 program
BMS-986089PHASE_1
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Bismuth subsalicylatePHASE_11 trial
Active Trials
NCT05930197Completed34Est. Dec 2024
Edgewise Therapeutics
1 program
EDG-15400PHASE_11 trial
Active Trials
NCT07177066Recruiting108Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerPF-07248144
PfizerPF-07220060
PfizerVaccine Candidate #1
PfizerPF-07104091
PfizerPF-08049820
PfizerPF-07220060
PfizerPF-07248144
PfizerPF-07104091
Edgewise TherapeuticsEDG-15400
Dong-A STDiluted Intravenous DA-5217
PfizerPF-07940369
Metro BiotechNicotinamide Mononucleotide
PfizerPF-07220060
PfizerPF-07328948
Metro BiotechMIB-725

Showing 15 of 41 trials with date data

Clinical Trials (41)

Total enrollment: 3,894 patients across 41 trials

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Start: Aug 2025Est. completion: Nov 2030400 patients
Phase 3Recruiting

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Start: Jan 2025Est. completion: Dec 20371,020 patients
Phase 3Recruiting
NCT07431853PfizerVaccine Candidate #1

A Study to Learn About mRNA Vaccines Against Influenza in Adults

Start: Feb 2026Est. completion: Jun 2027770 patients
Phase 2Recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Start: Sep 2020Est. completion: Dec 2026157 patients
Phase 2Active Not Recruiting

A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.

Start: Nov 2025Est. completion: Dec 202518 patients
Phase 1Active Not Recruiting

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

Start: Sep 2025Est. completion: Dec 202525 patients
Phase 1Completed

A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

Start: Sep 2025Est. completion: Jan 202612 patients
Phase 1Completed

A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants

Start: Aug 2025Est. completion: Nov 20259 patients
Phase 1Completed

A Study of EDG-15400 in Healthy Adults

Start: Aug 2025Est. completion: May 2026108 patients
Phase 1Recruiting
NCT07027982Dong-A STDiluted Intravenous DA-5217

A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

Start: Jul 2025Est. completion: Aug 202532 patients
Phase 1Completed

A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.

Start: Jul 2025Est. completion: Jan 202630 patients
Phase 1Completed
NCT06882096Metro BiotechNicotinamide Mononucleotide

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

Start: Apr 2025Est. completion: Jun 202732 patients
Phase 1Recruiting

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

Start: Mar 2025Est. completion: Jun 202514 patients
Phase 1Completed

A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults

Start: Mar 2025Est. completion: Jun 202526 patients
Phase 1Completed

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

Start: Feb 2025Est. completion: Mar 202732 patients
Phase 1Recruiting

A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults

Start: Feb 2025Est. completion: Jul 202524 patients
Phase 1Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

Start: Oct 2024Est. completion: Jul 202524 patients
Phase 1Completed

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

Start: May 2024Est. completion: Aug 202421 patients
Phase 1Completed

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

Start: Dec 2023Est. completion: Jul 202438 patients
Phase 1Completed
NCT05930197Allergy TherapeuticsBismuth subsalicylate

Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults

Start: Aug 2023Est. completion: Dec 202434 patients
Phase 1Completed

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

Start: Jul 2021Est. completion: Sep 202116 patients
Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

Start: Apr 2021Est. completion: Nov 202118 patients
Phase 1Completed

A Study to Evaluate LY06006 and Prolia in Healthy Adults

Start: Dec 2020Est. completion: Dec 2021168 patients
Phase 1Unknown
NCT04249323Corcept TherapeuticsCORT113176 Lipid Capsule Formulation

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Start: Jan 2020Est. completion: Oct 2020110 patients
Phase 1Completed

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Start: Dec 2019Est. completion: Jun 2021168 patients
Phase 1Unknown
NCT04228302Human BioSciencesEC5026 oral capsule

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

Start: Dec 2019Est. completion: Jul 202040 patients
Phase 1Completed

A Study to Evaluate the Denosumab in Healthy Adults

Start: Jan 2018Est. completion: Dec 201932 patients
Phase 1Unknown

Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.

Start: Dec 2015Est. completion: Jan 201643 patients
Phase 1Completed
NCT01889173Tonix PharmaceuticalsTNX-102 SL Tablets at 2.8 mg

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Start: Jun 2013Est. completion: Mar 201424 patients
Phase 1Completed

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

Start: Sep 2012Est. completion: Mar 201424 patients
Phase 1Completed
NCT01634412Tonix PharmaceuticalsSL TNX-102 2.4 mg at pH 3.5

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

Start: Jun 2012Est. completion: Jan 201424 patients
Phase 1Completed
NCT01367535Bausch HealthSC Methylnaltrexone

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Start: Mar 2006Est. completion: Aug 200654 patients
Phase 1Completed

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

Start: Oct 2005Est. completion: Mar 200637 patients
Phase 1Completed

Pilot Study of the Entarik System With Advanced Functionality in Health Adults

Start: Oct 2024Est. completion: Dec 202540 patients
N/ARecruiting

Adult HMO Supplementation and the Gut Microbiome

Start: Aug 2024Est. completion: Jul 202532 patients
N/ACompleted
NCT06376175Lumos PharmaTask Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program

Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program

Start: Apr 2024Est. completion: Jan 202537 patients
N/ACompleted

Enhancing the Benefits of Blueberry Polyphenols With Protein

Start: Mar 2023Est. completion: Jun 202419 patients
N/ACompleted
NCT04206293AbbVieJuvederm® VOLITE

A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers

Start: Oct 2019Est. completion: Jul 202011 patients
N/ACompleted

Evaluation of Spot Urine as a Biomarker of Fluid Intake in Real Life Conditions

Start: Oct 2013Est. completion: Mar 201482 patients
N/ACompleted

Pilot Study of a Dietary Intervention Based Upon Advanced Glycation End Products

Start: Oct 2011Est. completion: Nov 201124 patients
N/ACompleted
NCT01583387Innovation Pharmaceuticals1-Increased water intake regimen

Effect of Water Intake on the DNA Adducts Formation

Start: Feb 2011Est. completion: Oct 201165 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 actively recruiting trials targeting 3,894 patients
20 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.